# NCI National Clinical Trials Network (UG1)

> **NIH NIH UG1** · DUKE UNIVERSITY · 2020 · $463,561

## Abstract

Abstract
The Duke University School of Medicine is applying to continue our participation in the National
Clinical Trials Network (NCTN) as a Lead Academic Participating Site. The goal of this NCI
grant funding is to provide support for ongoing as well as future scientific leadership and clinical
trial infrastructure within the Duke Cancer Institute (DCI) in the development and conduct of
clinical trials. The award will further Duke's leadership and substantial accrual to NCI-funded
clinical trials, specifically multi-center, late-phase clinical treatment trials and imaging trials
across a broad range of cancers, modalities, and diverse patient populations as part of NCI’s
overall clinical research program for adults, adolescents, young adults and children with cancer.
An important focus will be an emphasis on trials in special populations, including underserved
populations and rare tumors. The leadership of the 6 Principal Investigators named in the grant
application, along with the faculty of the 8 NCI approved research programs at Duke and the
Duke Central NCTN Office, will provide a strong and efficient backbone for NCTN clinical
research, scientific leadership and patient enrollment effort. Our continued participation as a
member of the Alliance, NRG, ECOG-ACRIN, COG, ETCTN and enrollment in trials offered by
all adult NCI funded NCTN Network Groups, including SWOG through the Cancer Trials
Support Unit (CTSU) mechanism, gives Duke the experience and knowledge needed to lead
and enroll in complex NCI funded research involving multiple cancer sites and treatment
modalities. The definitive evaluation of newly developed therapies for cancer care including
multi-modality treatments, combinations of novel agents, immune approaches and molecularly-
based treatment along with advanced imaging approaches, will benefit patients and
practitioners as well as the entire oncology research community. This grant will also help to
foster an ideal environment to enhance multidisciplinary collaborations and develop the next
generation of clinical investigators dedicated to cancer research. The support provided to Duke
as a Lead Academic Participating Site will be leveraged against the significant scientific and
clinical resources of the Duke Cancer Institute to provide robust participation in a nationally
established clinical trial program.

## Key facts

- **NIH application ID:** 9888348
- **Project number:** 5UG1CA233253-02
- **Recipient organization:** DUKE UNIVERSITY
- **Principal Investigator:** DANIEL P BARBORIAK
- **Activity code:** UG1 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $463,561
- **Award type:** 5
- **Project period:** 2019-03-06 → 2025-02-28

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9888348

## Citation

> US National Institutes of Health, RePORTER application 9888348, NCI National Clinical Trials Network (UG1) (5UG1CA233253-02). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/9888348. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*